Circulating Tumor Cells
The circulating tumor cells or CTCs remain promising for pre-diagnosis, post-treatment, and intra procedure cancer treatment. Growing clinical research for development, and enrichment of CTC also promise to bring new innovations improving efficiency, and quality. CTC remains a gold standard in cancer diagnosis, as it leads to limited trauma, and invasive screening. This is essential for usually painful procedures including radiotherapy, chemotherapy, and surgical removal of tumors. The limitation feasibility of CTCs in rare cancers still remains a challenge to their commercial application. Growing cancer incidences, and increased private, and public funding for chronic illness research remain key drivers of growth in the circulating tumor cells market.
Circulating Tumor Cells Market: An Overview
Circulating tumor cell or CTC which are primarily shed from lymphatics and then carried around the body in the blood circulation. These then become seed for subsequent growth of additional tumors. Such process is also known as metastasis, and is responsible for majority of fatalities in cancer cases. The CTC is increasingly touted as a gold standard in cancer detection, as it is both FDA approved for safety, and remains a primary mechanism for early detection. The method is key to early detection of breast, prostate, and colorectal cancer.
Request a Sample Report: @ https://brandessenceresearch.com/requestSample/PostId/1434
Circulating tumor cells are primarily targeted to identify, and quantify EpCAM protein produced by epithelial tumor cells. These tests are usually mandated before procedures and during cancer treatment as well. The CTC tests help in determining course procedure, as well as treatment efficacy. Furthermore, these tests are non-invasive as these are liquid biopsies, that obtain the necessary cell count from blood samples. Conventionally, understanding solid tumors required invasive procedures, which were dangerous and limited reach among elderly population. Recently, developments in field have improved sensitivity, and reproducibility to detect metastatic spread. CTCs are very rare, and are usually only a few cells per millimeter of blood. This makes detecting CTCs very challenging. Furthermore, CTCs are usually diagnosed in collaboration with various different diagnosis technique as its markers can vary from patient to patient. Growing standardization, and increased understanding of margin, and non-invasive nature of the treatment remain key drivers of the circulating tumor cell market.
According to Brandessence Market Research, the circulating tumor cells market size reached USD 19.33 billion by 2028 end. The market is expected to grow at robust pace, or CAGR of 11.75% during 2021-2028 period.
Growing Burden of Cancer Remains a Major Driver for Growth
According to the World Cancer Research Fund, in 2018, there were 18 million of cancers around the world. These cases continue to remain underreported due to limited reach of research facilities, and high-costs of diagnosis, and treatment. Furthermore, lung and breast cancer remain leading cancers with highest diseases. The growing awareness of breast cancer with increased encouragement for diagnosis promise increased opportunities for growth for players in the CTC market.
Request for Methodology of this report: https://brandessenceresearch.com/requestMethodology/PostId/1434
In regions where detection of cancer remains really high. An example of this is North America, wherein in some parts, cancer penetration remains as high as 21%. The increased lifestyle trends and worsening environmental conditions make rise of cancer a worrying trend globally. However, in terms of solutions, cancer diagnosis, prognosis, and treatment remain limited. The growing elderly population, and increased prevalence of cancer incidences remains a major dynamic in the CTC market. In countries like the US, the expansion of healthcare policy to include everyone over 65, and increased access to affordable treatment remains a major promise for growth for early and safe detection of circulating tumor cells market.
Circulating Tumor Cells Market: Regional Analysis
The circulating tumor cells market report is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Among these, North America is expected to hold the highest share of total revenues during the forecast period. The growing cases of cancer in this region, immense reach of healthcare facilities, and growing awareness of early detection for breast cancer remain key promise for growth in this region. The growing awareness of CTC detection methods in new regions like Asia Pacific also remains a major promise. The increased healthcare facilities in India, and China, and large population in the region remain key drivers for fastest futuristic growth in Asia Pacific.
Circulating Tumor Cells Market: Competitive Analysis
The circulating tumor cells market is a competitive, innovative, and fragmented landscape. The growing need for improvements, and increased funding for clinical research remain key drivers of innovation in the CTC market. collaboration, acquisition, and mergers remain key opportunities as market share remains fragmented among several small players. Some key global players in the circulating tumor cells market are Janssen Diagnostics, Aviva Biosciences, Advanced Cell Diagnostics, Biofluidica Inc, CellTraffix Inc, and Biocept Inc.
Circulating Tumor Cells Market: Notable News
- According to a new study published in Nature journal, nanostructured titanium oxide coated slides detected clustered CTCs in patients in the early stages of breast cancer. Earlier, studies remained unclear whether CTC technology promises to detect breast cancer in their earliest stages, wherein metastasis-free primary disease was present. Hence, CTC technology can now potentially detect breast cancer even earlier than previously anticipated.
- Janssen Diagnostics announced that its flagship CELLSEARCH system technology has a proven ability to detect PD-L1 expression on circulating tumor cells. These findings were published in Molecular Oncology, wherein 68.8% were patients were detected with PD-L1 positive in CTCs.
- BioFluidica announced its plan to commercialize a standardized biomarker enrichment solution. The technology known as LiquidScan is said to enable maximum performance for a broad variety of validated applications including key applications like solid tumors, and leukemic cancers. The biomarker also shows promise for non-invasive prenatal screening, and viral pathogens including SARS-CoV-2.
Complete Access of Report@ https://brandessenceresearch.com/healthcare/circulating-tumor-cells-market-report
Related Report:
28.51% CAGR , mRNA Vaccines & Therapeutics Market Size, Share, significant growth Rate, Trends 2026 by Brandessence Market Research
Home Healthcare Market projected to exceed $ 293.6 billion by 2026, Says Brandessence Market Research
At 3.99% CAGR, Medical Imaging Market Size is Expected to reach USD 35.78 Billion in 2027 Says Brandessence Market Research
Vaccines Vials Market Size is Projected to reach USD 901.3 Million by 2027, Says Brandessence Market Research
Growing At 9.9% CAGR, Patient Engagement Solutions Market Size is Projected to Exceed USD 23.05 Billion by 2027, Says Brandessence Market Research
About Us:
We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.
Contact Us:
Contact No.: +91 7447409162, +44-2038074155, 1-888-853-7040